Protein expression of various hepatic uridine 5′-diphosphate glucuronosyltransferase (UGT) enzymes and their intercorrelations: A meta-analysis

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 6, 2014, Pages 353-361

  Achour, Brahim ^a   Rostami Hodjegan, Amin ^a,b   Barber, Jill ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Abundance; Correlation of expression; In vitro in vivo extrapolation; Inter individual variability; Uridine 5 diphosphate glucuronosyltransferase

Indexed keywords

DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; UNCLASSIFIED DRUG;

ARTICLE; CORRELATIONAL STUDY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GLUCURONIDATION; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; LABORATORY TEST; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MATHEMATICAL ANALYSIS; META ANALYSIS; METABOLIC PARAMETERS; PHYSIOLOGICAL PROCESS; POPULATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; BIBLIOGRAPHIC DATABASE; LIVER; METABOLISM;

DATABASES, BIBLIOGRAPHIC; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER;

EID: 84922256531     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1906     Document Type: Article

References (35)

1. Ritter JK. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 2007; 3: 93-107.
2. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005; 4: 825-833.
3. Walsky RL, Bauman JN, Bourcier K, et al. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 2012; 40: 1051-1065.
4. Miners JO, Mackenzie PI, Knights KM. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 2010; 42: 189-201.
5. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
6. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 40-48.
7. Jover R, Moya M, Gómez-Lechón MJ. Transcriptional regulation of cytochrome P450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr Drug Metab 2009; 10: 508-519.
8. Sánchez-Meca J, Martín-Martínez F. Homogeneity tests in meta-analysis: a Monte Carlo comparison of statistical power and Type I error. Qual Quant 1997; 31: 385-399.
9. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
10. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
12. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research (4th edn). Wiley- Blackwell: Oxford, 2001.
13. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 2012; 40: 83-92.
14. Fallon JK, Harbourt DE, Maleki SH, Kessler FK, Ritter JK, Smith PC. Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS. Drug Metab Lett 2008; 2: 210-222.
15. Harbourt DE, Fallon JK, Ito S, et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 2011; 84: 98-105.
16. Sridar C, Hanna I, Hollenberg PF. Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches. Xenobiotica 2013; 43: 336-345.
17. Sato Y, Nagata M, Kawamura A, Miyashita A, Usui T. Protein quantification of UDP-glucuronosyltransferase 1A1 and 2B7 in human livermicrosomes by LC-MS/MS and correlation with glucuronidation activities. Xenobiotica 2012; 42: 823-829.
18. Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res 2013; 12: 4402-4413.
19. Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 2014; 42: 500-510.
20. Sato Y, Nagata M, Tatsuka K, et al. Optimized methods for the targeted peptide-based quantification of human uridine 5′-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2014; 42: 885-889.
21. Milne AM, Burchell B, Coughtrie MWH. A novel method for the immunoquantification of UDP-glucuronosyltransferases in human tissue. Drug Metab Dispos 2011; 39: 2258-2263.
22. Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013; 45: 1121-1132.
23. Izukawa T, Nakajima M, Fujiwara R, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 2009; 37: 1759-1768.
24. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010; 42: 209-224.
25. Russell MR, Achour B, Mckenzie EA, et al. Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res 2013; 12: 5934-5942.
26. Bock KW. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyltransferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem Pharmacol 2010; 80: 771-777.
27. Ramírez J, Mirkov S, Zhang W, et al. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J 2008; 8: 152-161.
28. Aueviriyavit S, Furihata T, Morimoto K, Kobayashi K, Chiba K. Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metab Pharmacokinet 2007; 22: 391-398.
29. Zhou J, Zhang J, Xie W. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyltransferases. Curr Drug Metab 2005; 6: 289-298.
30. Nakamura A, Nakajima M, Higashi E, Yamanaka H, Yokoi T. Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 2008; 18: 709-720.
31. Senekeo-Effenberger K, Chen S, Brace-Sinokrak E, et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor α activation. Drug Metab Dispos 2007; 35: 419-427.
32. Barbier O, Villeneuve L, Bocher V, et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J Biol Chem 2003; 278: 13975-13983.
33. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchard JC, Staels B. Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 2003; 278: 32852-32860.
34. Achour B, Barber J, Rostami-Hodjegan A. Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their inter-correlations: a meta-analysis. Drug Metab Dispos 2014; 42: 1349-1356.
35. Wells PG, Mackenzie PI, Chowdhury JR, et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 2004; 32: 281-290.